Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

Abstract : BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentan-monotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily. The primary end point in a time-to-event analysis was the first event of clinical failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clinical response.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.univ-grenoble-alpes.fr/hal-01969356
Contributeur : Sarah Hamant <>
Soumis le : vendredi 4 janvier 2019 - 09:06:33
Dernière modification le : mercredi 15 juillet 2020 - 09:10:04

Lien texte intégral

Identifiants

Collections

Citation

Nazzareno Galié, Joan Barberà, Adaani Frost, Hossein-Ardeschir Ghofrani, Marius Hoeper, et al.. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, Massachusetts Medical Society, 2015, 373 (9), pp.834-844. ⟨10.1056/NEJMoa1413687⟩. ⟨hal-01969356⟩

Partager

Métriques

Consultations de la notice

227